Cargando…
Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens.
Peripheral blood mononuclear cells (PBMCs) were obtained from patients receiving radioactive murine monoclonal antibody (MAb) therapy for malignant epithelial tumours, as well as normal controls, and were tested for the ability of T cells to proliferate in vitro in the presence of the MAb administer...
Autores principales: | Kosmas, C., Epenetos, A. A., Courtenay-Luck, N. S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977633/ https://www.ncbi.nlm.nih.gov/pubmed/1911190 |
Ejemplares similares
-
Monoclonal antibodies for imaging and therapy.
por: Epenetos, A. A., et al.
Publicado: (1989) -
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005) -
Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody.
por: Hird, V., et al.
Publicado: (1993) -
Therapy of murine leukemia with monoclonal antibody against a normal differentiation antigen
Publicado: (1983) -
Development of a novel bi-specific monoclonal antibody approach for tumour targeting
por: Koumarianou, A A, et al.
Publicado: (1999)